SCHEMBL31663775

SCHEMBL31663775

CC(C)(C)OC(=O)N1CCCC[C@@H]1COc1ccc(NC(=O)C2CC2)cc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.43
RAB9A P51151 1/20 0.43
FPR3 P25089 1/20 0.42
FPR2 P25090 1/20 0.42
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM1A O60341 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37
JAK2 O60674 2/20 0.36
USP30 Q70CQ3 1/20 0.36
MALT1 Q9UDY8 1/20 0.36
F2RL3 Q96RI0 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31663794 1.00 NPC1 (0.43) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663769 1.00 NPC1 (0.43) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663785 0.94 NPC1 (0.43) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663815 0.83 FPR3 (0.49) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663772 0.83 FPR3 (0.49) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663765 0.78 NPC1 (0.44) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663763 0.78 NPC1 (0.44) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663788 0.78 NPC1 (0.44) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL29619014 0.78 NPC1 (0.42) NPC1RAB9AFPR3FPR2ABL1
SCHEMBL31663780 0.77 NPC1 (0.48) NPC1RAB9AFPR3FPR2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-4236937-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2025-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto HTR2A, HTR5A, HTR1A NPC1 2828/4885RAB9A 1679/4885FPR3 1196/4885
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto HTR2C, HTR1A, HTR2A NPC1 612/4885RAB9A 1906/4885FPR3 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.